Intelligencia’s mission is bringing new therapies to patients faster. We combine exceptional data with the computational power of AI to improve your probability of clinical success and enhance your sourcing of external innovation. Our customers – large pharmaceutical companies, and biotechs ranging from multi-billion large-cap to emerging preclinical – use Intelligencia’s platform to (i) assess the probability of success (PTRS) of their development programs and minimize any risks, (ii) optimize trial design and evaluate additional indications for a clinical asset, (iii) evaluate the relative attractiveness external assets, and (iv) predict likely future areas of scientific innovation. With offices in the US and Europe, our team is made up of industry veterans, data scientists, bioinformaticians, software engineers, biologists, and drug developers.

Learn more at intelligencia.ai